{
    "clinical_study": {
        "@rank": "122755", 
        "arm_group": {
            "arm_group_label": "Tresiba\u00ae users"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to\n      assess safety and effectiveness of long-term treatment with Tresiba\u00ae (insulin degludec) in\n      patients with diabetes mellitus requiring insulin therapy under normal clinical practice\n      conditions.\n\n      A total of 4000 patients will be enrolled to investigate long term (3 years of treatment)\n      safety of Tresiba\u00ae and additional 2000 patients will be enrolled to assess the safety in an\n      early stage of the PMS more precisely. At the time of enrolment the patients will be\n      randomly allocated to either 3 years or 6 months observation group."
        }, 
        "brief_title": "Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba\u00ae", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with diabetes mellitus requiring insulin therapy for whom the treating\n             physician has decided to start Tresiba\u00ae treatment\n\n        Exclusion Criteria:\n\n          -  Patients who are or have previously been on Tresiba\u00ae therapy\n\n          -  Patients who have previously been participating in this PMS"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with diabetes mellitus requiring insulin therapy not previously treated with\n        Tresiba\u00ae, including newly-diagnosed patients whom the physician has judged as appropriate\n        to start treatment with Tresiba\u00ae."
            }
        }, 
        "enrollment": {
            "#text": "6000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984372", 
            "org_study_id": "NN1250-4061", 
            "secondary_id": "U1111-1144-4412"
        }, 
        "intervention": {
            "arm_group_label": "Tresiba\u00ae users", 
            "description": "Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.", 
            "intervention_name": "insulin degludec", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 13, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "1000005"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-centre, Open Label, Observational, Non-interventional, Post Marketing Surveillance to Evaluate Safety and Effectiveness During Long-term Treatment With Tresiba\u00ae (Insulin Degludec) in Patients With Diabetes Mellitus Requiring Insulin Therapy Under Normal Clinical Practice Conditions", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of AEs (Adverse Events) by preferred term", 
            "safety_issue": "No", 
            "time_frame": "During 3 years of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984372"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of AEs (Adverse Events) by preferred term", 
                "safety_issue": "No", 
                "time_frame": "During 6 months of treatment"
            }, 
            {
                "measure": "Incidence of SADRs (Serious Adverse Drug Reactions) by preferred term", 
                "safety_issue": "No", 
                "time_frame": "During 6 months of treatment"
            }, 
            {
                "measure": "Incidence of SADRs (Serious Adverse Drug Reactions) by preferred term", 
                "safety_issue": "No", 
                "time_frame": "During 3 years of treatment"
            }, 
            {
                "measure": "Incidence of serious allergic reactions (systemic or localized, including injection site reactions) by preferred term", 
                "safety_issue": "No", 
                "time_frame": "During 6 months of treatment"
            }, 
            {
                "measure": "Incidence of serious allergic reactions (systemic or localized, including injection site reactions) by preferred term", 
                "safety_issue": "No", 
                "time_frame": "During 3 years of treatment"
            }, 
            {
                "measure": "Incidence of severe hypoglycaemia", 
                "safety_issue": "No", 
                "time_frame": "During 6 months of treatment"
            }, 
            {
                "measure": "Incidence of severe hypoglycaemia", 
                "safety_issue": "No", 
                "time_frame": "During 3 years of treatment"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}